PCA3 Test Now Offered at Dr. Samadi's Prostate Cancer Center

Jul 28, 2015, 03:37 ET from Dr. David Samadi

NEW YORK, July 28, 2015 /PRNewswire/ -- Dr. David Samadi's Prostate Cancer Center is now offering the PCA3 test for prostate cancer screening.

The PCA3 test is a simple urine sample collected following a digital rectal exam for the determination of the PCA3 score. Specific for prostate cancer, and, unlike the PSA, this test is not affected by prostate enlargement or other non-cancerous prostate conditions. In combination with PSA and DRE results, the PCA3 score provides useful information to help decide if a biopsy is needed, or can be delayed. It's much more specific in giving additional information about the aggressiveness of the cancer if the patient has a positive biopsy.

"This new genetic test is a great next step for some men with an elevated PSA. The purpose of this tumor marker test is to reduce unnecessary biopsies. Not every elevated PSA translates to the need for a biopsy. The PCA3 test was specifically developed to address the criticisms of the PSA being non-specific to prostate cancer. Combined with the PSA and DRE, this new genetic test helps lead to a more optimized decision to perform the biopsy," stressed Dr. David Samadi, Chairman of Urology and Chief of Robotic Surgery at Lenox Hill Hospital in New York City.

The PCA3 test is not meant to replace the PSA test. It is simply an additional tool used to provide a more accurate picture and prediction of whether prostate cancer is present or not. It is intended to be used in combination with the traditional prostate cancer screening tools (PSA test, DRE) to help decide whether a prostate biopsy is really necessary in men who are suspected of having prostate cancer. This includes men who have a suspicious DRE and/or an elevated PSA and men who have had one or more negative biopsies. If a prostate biopsy determines prostate cancer is present, the PCA3 test may also help predict the risk of tumor progression and the aggressiveness of the tumor, which will help determine how early treatment is needed.

The higher the PCA3 score, the more likely that prostate cancer will be found in the prostate biopsy. Therefore, a prostate biopsy is recommended. If the PCA3 score is low, a prostate biopsy may be unnecessary or at least delayed for some time. 

If a man's PSA is elevated, the 4K ScorePCA3, and Prostate Biopsy can further indicate activity around the prostate as well as support whether to get a biopsy or not. If a biopsy returns positive, the next step is directing the right prostate cancer treatment for each patient.

Dr. Samadi's Prostate Cancer Center is the only center in New York City using the revolutionary UroNav Fusion Biopsy System for MRI-Guided Biopsy. An MRI-ultrasound fusion biopsy involves taking an MRI and then fusing the data with real-time ultrasound images for guidance on biopsy procedures. The UroNav System combines electromagnetic tracking and navigation with an onboard computer and a real-time imaging interface in one mobile workstation. The MR/Ultrasound fusion aligns and registers prior diagnostic MR images with real-time ultrasound images.

Patients newly diagnosed with prostate cancer can contact world renowned prostate cancer surgeon and urologic oncologist, Dr. David Samadi, for a consultation. Visit ProstateCancer911.com and call 212.365.5000 to set up your consultation.

Photo - http://photos.prnewswire.com/prnh/20150728/246610

SOURCE Dr. David Samadi